$XBI $93.26 | +3.76%
Pipeline Updates
$CYTK Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session
$GILD Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
$IBRX ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
$YMAB Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
$PRAX PRAXIS PRECISION MEDICINES TO PRESENT DATA FROM PRAX-944 FOR ESSENTIAL TREMOR AT 2022 AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
$NBIX Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
$LBPH Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting
$OCGN OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL TRIAL FOR GENE THERAPY CANDIDATE OCU400 TO TREAT INHERITED RETINAL DEGENERATION
$ALT Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
$AMRN Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes
$CLNN Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
$ANEB Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission.
Business Updates
$SLNO Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering
$JAGX Jaguar Health Enters Exclusive Crofelemer Revenue Sharing Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
$BHVN NURTEC (RIMEGEPANT) LACTATION CLINICAL STUDY PUBLISHED IN BREASTFEEDING MEDICINE JOURNAL
$SYBX Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting
$ARAV Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$SLS SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering.
Posted by DV
Comments